1 Gene Therapy Program, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
2 Department of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Hum Gene Ther. 2018 Jan;29(1):15-24. doi: 10.1089/hum.2017.026. Epub 2017 Oct 3.
Delivery of adeno-associated viral (AAV) vectors into the cerebrospinal fluid (CSF) can achieve gene transfer to cells throughout the brain and spinal cord, potentially making many neurological diseases tractable gene therapy targets. Identifying the optimal route of CSF access for intrathecal AAV delivery will be a critical step in translating this approach to clinical practice. We previously demonstrated that vector injection into the cisterna magna is a safe and effective method for intrathecal AAV delivery in nonhuman primates; however, this procedure is not commonly used in clinical practice. More routine methods of administration into the CSF are now being explored, including intracerebroventricular (ICV) injection and injection through a lumbar puncture. In this study, we compared ICV and intracisternal (IC) AAV administration in dogs. We also evaluated vector administration via lumbar puncture in nonhuman primates, with some animals placed in the Trendelenburg position after injection, a maneuver that has been suggested to improve cranial distribution of vector. In the dog study, ICV and IC vector administration resulted in similarly efficient transduction throughout the brain and spinal cord. However, animals in the ICV cohort developed encephalitis associated with a T-cell response to the transgene product, a phenomenon that was not observed in the IC cohort. In the nonhuman primate study, transduction efficiency was not improved by placing animals in the Trendelenburg position after injection. These findings illustrate important limitations of commonly used methods for CSF access in the context of AAV delivery, and will be important for informing the selection of a route of administration for first-in-human studies.
腺相关病毒(AAV)载体递送至脑脊液(CSF)可以实现对大脑和脊髓中细胞的基因转移,这使得许多神经疾病成为可行的基因治疗靶标。确定 CSF 进入的最佳途径对于将这种方法转化为临床实践将是至关重要的一步。我们之前证明,将载体注入枕大池是在非人灵长类动物中进行鞘内 AAV 递送的一种安全有效的方法;然而,这种程序在临床实践中并不常用。现在正在探索更常规的 CSF 给药方法,包括脑室内(ICV)注射和通过腰椎穿刺注射。在这项研究中,我们比较了 ICV 和颅内(IC)AAV 给药在犬中的效果。我们还评估了在非人灵长类动物中通过腰椎穿刺进行的载体给药,其中一些动物在注射后被置于特伦德伦伯格体位,这种操作被认为可以改善载体的颅分布。在犬研究中,ICV 和 IC 载体给药导致大脑和脊髓的转导效率相似。然而,ICV 组的动物发生了与转基因产物的 T 细胞反应相关的脑炎,而在 IC 组中没有观察到这种现象。在非人类灵长类动物研究中,将动物置于特伦德伦伯格体位后注射并没有提高转导效率。这些发现说明了在 AAV 递送上,常用 CSF 进入方法的重要局限性,这对于为首次人体研究选择给药途径将是重要的。